RGNX REGENXBIO Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RGNX

Price (delayed)

$7.5

Market cap

$495.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.79

Enterprise value

$707.04M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 25

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is ...

Highlights
RGNX's gross profit has soared by 152% since the previous quarter and by 17% year-on-year
The company's revenue has surged by 99% QoQ and by 12% YoY
RGNX's EPS is up by 32% since the previous quarter but it is down by 10% year-on-year
The net income is up by 32% from the previous quarter but it is down by 12% YoY
The equity has plunged by 66% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.regenxbio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RGNX

RGNX stock price

How has the REGENXBIO stock price performed over time
Intraday
-7.98%
1 week
-6.02%
1 month
-30.04%
1 year
-16.01%
YTD
-47.92%
QTD
-37.4%

Financial performance

How have REGENXBIO's revenue and profit performed over time
Revenue
$174.48M
Gross profit
$150.71M
Operating income
-$164.15M
Net income
-$196.43M
Gross margin
86.4%
Net margin
-112.6%
RGNX's gross profit has soared by 152% since the previous quarter and by 17% year-on-year
The company's revenue has surged by 99% QoQ and by 12% YoY
RGNX's operating margin has soared by 68% since the previous quarter and by 11% year-on-year
REGENXBIO's net margin has surged by 66% QoQ

Price vs fundamentals

How does RGNX's price correlate with its fundamentals

Growth

What is REGENXBIO's growth rate over time

Valuation

What is REGENXBIO stock price valuation
RGNX P/E details
P/E
N/A
P/B
5.4
P/S
2.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.05
RGNX's EPS is up by 32% since the previous quarter but it is down by 10% year-on-year
The equity has plunged by 66% YoY
RGNX's P/B is 63% above its 5-year quarterly average of 3.6 but 40% below its last 4 quarters average of 9.8
The company's revenue has surged by 99% QoQ and by 12% YoY
The price to sales (P/S) is 59% lower than the 5-year quarterly average of 6.0 and 38% lower than the last 4 quarters average of 4.0

Efficiency

How efficient is REGENXBIO business performance
RGNX's return on sales has surged by 68% since the previous quarter and by 5% year-on-year
REGENXBIO's ROA has decreased by 35% YoY but it has increased by 25% from the previous quarter
The ROIC has grown by 33% from the previous quarter and by 3.7% YoY
The ROE is up by 5% QoQ

Dividends

What is RGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGNX.

Financial health

How did REGENXBIO financials performed over time
RGNX's total assets is 23% greater than its total liabilities
RGNX's total assets is down by 33% year-on-year but it is up by 13% since the previous quarter
RGNX's total liabilities is down by 14% year-on-year
RGNX's debt to equity has soared by 175% year-on-year but it has dropped by 70% since the previous quarter
The equity has plunged by 66% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.